Last reviewed · How we verify
Randomisation course 2 ADxE versus FLADx — Competitive Intelligence Brief
phase 3
Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
Randomisation course 2 ADxE versus FLADx (Randomisation course 2 ADxE versus FLADx) — Vastra Gotaland Region. ADxE and FLADx are both involved in the regulation of the immune system.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Randomisation course 2 ADxE versus FLADx TARGET | Randomisation course 2 ADxE versus FLADx | Vastra Gotaland Region | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Randomisation course 2 ADxE versus FLADx CI watch — RSS
- Randomisation course 2 ADxE versus FLADx CI watch — Atom
- Randomisation course 2 ADxE versus FLADx CI watch — JSON
- Randomisation course 2 ADxE versus FLADx alone — RSS
Cite this brief
Drug Landscape (2026). Randomisation course 2 ADxE versus FLADx — Competitive Intelligence Brief. https://druglandscape.com/ci/randomisation-course-2-adxe-versus-fladx. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing